In addition to SAM analogues used in Parkinson therapy, protein lysine and arginine MT inhibitors demonstrated therapeutic activities in human cancers.[57] With the discovery of α‐N‐terminal MT 1 (NTMT1) and its physiological substrates, its possible participation in the response to DNA damage and cancer development was suggested.[58] The protein methylation of an α‐N terminus by NTMT differs from the methylation of the side chain of lysine or arginine residues by protein lysine and arginine MT in that both, hydrophobicity and charge state, are altered under physiological conditions. This evidence concerns the gene MCAT and Parkinson disease.